Abstract: The present invention relates to vaccines that are made in transgenic soybeans for use in humans, animals of agricultural importance, pets, and wildlife. These vaccines are used as vaccines against viral, bacterial, fungal, parasitic or prion related diseases, cancer antigens, toxins, and autologous or self proteins. The transgenic soybeans of the instant invention also can be used for inducing tolerance to allergens or tolerance to autoimmune antigens, wherein an individual shows hypersensitivity to said allergen or has developed autoimmunity to autologous or self proteins, respectively. The invention also relates to prophylatically treating individuals and/or populations prior to showing hypersensitivity to allergens. Other aspects of the invention include using the transgenic soybeans as an oral contraceptive, and the expression of protein adjuvants in transgenic soybeans.

Abstract: A strategy for eliminating or greatly reducing the need for physical/chemical treatments or the use of whole microbes for lignocellulosic biomass and organopollutant degradation is disclosed. The soybean is a practical, cost-efficient and sustainable bioreactor for the production of lignin-degrading and cellulose-degrading enzymes. The use of soybean as a transgenic overexpression platform provides advantages that no other industrial scale enzyme expression system can match. Availability of a battery of related plant biomass degrading enzymes in separate transgenic soybean lines provides unprecedented flexibility in industrial and bioremediation processes. Depending upon the particular application, selected soybean-derived powdered enzyme formulations can be used, and their sequential addition can be orchestrated.

Abstract: The present invention includes novel soybean derived human thyroglobulin, methods of producing human thyroglobulin in plants such as soybean, and novel diagnostic applications for the detection and stratification of endocrine malignancies including thyroid cancer and thyroiditis. The invention also includes the use of soybean-derived human thyroglobulin in affinity matrices to remove autoreactive anti-thyroglobulin antibodies from patient's sera prior to analyses. Moreover, the invention also includes methods and compositions of treating, preventing and or/ameliorating symptoms associated with thyroiditis.

Abstract: A strategy for eliminating or greatly reducing the need for physical/chemical treatments or the use of whole microbes for lignocellulosic biomass and organopollutant degradation is disclosed. The soybean is a practical, cost-efficient and sustainable bioreactor for the production of lignin-degrading and cellulose-degrading enzymes. The use of soybean as a transgenic overexpression platform provides advantages that no other industrial scale enzyme expression system can match. Availability of a battery of related plant biomass degrading enzymes in separate transgenic soybean lines provides unprecedented flexibility in industrial and bioremediation processes. Depending upon the particular application, selected soybean-derived powdered enzyme formulations can be used, and their sequential addition can be orchestrated.

Abstract: The present invention includes novel soybean derived human thyroglobulin, methods of producing human thyroglobulin in plants such as soybean, and novel diagnostic applications for the detection and stratification of endocrine malignancies including thyroid cancer and thyroiditis. The invention also includes the use of soybean-derived human thyroglobulin in affinity matrices to remove autoreactive anti-thyroglobulin antibodies from patient's sera prior to analyses. Moreover, the invention also includes methods and compositons of treating, preventing and or/ameliorating symptoms associated with thyroiditis.

Abstract: The present invention relates to vaccines that are made in transgenic soybeans for use in humans, animals of agricultural importance, pets, and wildlife. These vaccines are used as vaccines against viral, bacterial, fungal, parasitic or prion related diseases, cancer antigens, toxins, and autologous or self proteins. The transgenic soybeans of the instant invention also can be used for inducing tolerance to allergens or tolerance to autoimmune antigens, wherein an individual shows hypersensitivity to said allergen or has developed autoimmunity to autologous or self proteins, respectively. The invention also relates to prophylactically treating individuals and/or populations prior to showing hypersensitivity to allergens. Other aspects of the invention include using the transgenic soybeans as an oral contraceptive, and the expression of protein adjuvants in transgenic soybeans.

Abstract: The present invention relates to vaccines that are made in transgenic soybeans for use in humans, animals of agricultural importance, pets, and wildlife. These vaccines are used as vaccines against viral, bacterial, fungal, parasitic or prion related diseases, cancer antigens, toxins, and autologous or self proteins. The transgenic soybeans of the instant invention also can be used for inducing tolerance to allergens or tolerance to autoimmune antigens, wherein an individual shows hypersensitivity to said allergen or has developed autoimmunity to autologous or self proteins, respectively. The invention also relates to prophylatically treating individuals and/or populations prior to showing hypersensitivity to allergens. Other aspects of the invention include using the transgenic soybeans as an oral contraceptive, and the expression of protein adjuvants in transgenic soybeans.